Cargando…
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuse...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305753/ https://www.ncbi.nlm.nih.gov/pubmed/32636055 http://dx.doi.org/10.1016/j.cytogfr.2020.06.013 |